



Financial Tear Sheet

Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com (<http://www.alkermes.com>).

IR Contacts

Sandy Coombs
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6377
E-mail: Sandra.Coombs@alkermes.com (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6823
E-mail: eva.stroynowski@alkermes.com (<mailto:eva.stroynowski@alkermes.com>)

Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$51.09
Change (%)	0.39 (0.76%)
	▼
Volume	529,496
52 Week Low	\$42.64
Market Cap	\$7,850,327,802
Rolling EPS	-1.29
PE Ratio	N/A
Shares Outstanding	153,656,837
Data as of 10/18/17 4:00 p.m. ET	



Recent Headlines & Events

- 10/18/17 - 11:16 a.m.
New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2309542)
- 10/16/17 - 7:00 a.m.
Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2308696)
- 09/28/17 - 4:00 p.m.
Alkermes Participates in President's Commission Meeting on Combating Drug Addiction and the Opioid Crisis (phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2303572)

There are currently no events scheduled.

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Powered by **EDGAR**Online. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed